A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
R-Pharm
Seagen Inc.
Pfizer
Eli Lilly and Company
Pfizer
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Coherus Oncology, Inc.
Novartis
EMD Serono
Pfizer
Ohio State University Comprehensive Cancer Center
AstraZeneca
City of Hope Medical Center
GlaxoSmithKline
City of Hope Medical Center
Enliven Therapeutics
University of Alabama at Birmingham
Toray Industries, Inc
City of Hope Medical Center
DEKA Biosciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hansoh BioMedical R&D Company
IGM Biosciences, Inc.
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Tanta University
Hansoh BioMedical R&D Company
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Taiho Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Shanghai Zhongshan Hospital
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
Ludwig Institute for Cancer Research
Sumitomo Pharma Co., Ltd.
GSO Global Clinical Research BV
Gilead Sciences
Eli Lilly and Company
TG Therapeutics, Inc.
M.D. Anderson Cancer Center
mAbxience Research S.L.
Haihe Biopharma Co., Ltd.
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center